“We said our Covid-19 testing business would decline when we see the recovery from the pandemic, and it fell in the first half,” Rusckowski said “Closing bell.” “In the past few weeks, and we believe it is related to the Delta variant, we have also seen a slight increase in this Covid test volume.”
Rusckowski, who was CEO of Dutch healthcare technology company Philips Healthcare before joining Quest in 2012, said Quest is using next generation sequencing to provide Covid test results to centers for disease control and prevention. The majority of the positive tests the company identified this week were for the Delta variant, he said.
The highly communicable Delta Tribe is causing cases and deaths too increase again in the United States, especially in largely unvaccinated communities. This has at. Raised concerns Health professionals and local officials across the country, some of which have begun to reintroduce and advise against the mask requirement for indoor spaces for both vaccinated and unvaccinated people.
More than 162 million people in the United States are fully vaccinated – roughly 49% of the country’s population – although the rate of daily vaccinations continues to decline sharply. according to a CDC tracker.
While Rusckowski noted an increase in Covid tests, Dr. Scott Gottlieb CNBC said Thursday morning that while he believes the current surge in Delta infections may be over sooner than expected, it’s hard to confirm because people are being tested much less now than they used to be.
“Vaccinated people do not present for testing, and many young and healthy people who are currently mostly infected do not present for testing,” said Gottlieb, a former head of the Food and Drug Administration.
How the American healthcare system looks People return to personal doctor visits, Quest also released better-than-expected business results for the second quarter Recovery in its non-Covid services, such as tests for cancer, cardiovascular disease, infectious diseases, and neurology.
The New Jersey-based medical testing company reported adjusted earnings per share of $ 3.18 on sales of $ 2.55 billion. According to Refinitiv, analysts expected earnings per share of US $ 2.87 and sales of US $ 2.38 billion. Revenue was up 39.5% year over year when the company reported adjusted earnings per share of $ 1.42.
The company forecasts full-year sales between $ 9.54 billion and $ 9.79 billion.
“Our basic business decreased significantly in April last year. Our basic business was not over 50% and we only started our Covid tests in March of last year, ”said Rusckowski. “Today we actually have around 300,000 test capacities per day. That was still zero in March of last year. So, in the second quarter of last year, our basic business was in decline and we’re just starting to ramp up our Covid tests. “